Report: Beyond Chemotherapy Battling Cancer with Biotechnology TOC

INTRODUCTION

REASON FOR DOING STUDY
STUDY GOAL AND OBJECTIVES
WHO SHOULD READ THIS REPORT
METHODOLOGY AND INFORMATION SOURCES
ANALYSTS CREDENTIALS
OTHER RELEVANT RELATED BCC REPORTS AND PUBLICATIONS
BCC ON-LINE SERVICES
DISCLAIMER

EXECUTIVE SUMMARY

Summary Table:
PROJECTED GLOBAL REVENUES FROM BIOTECH-ENABLED CANCER THERAPIES BY APPLICATION TYPE, THROUGH 2008 ($ MILLION)
Summary Figure:
PROJECTED GLOBAL REVENUES FROM BIOTECH-ENABLED CANCER THERAPIES BY APPLICATION TYPE, THROUGH 2008 ($ MILLION)

OVERVIEW

GRIM STATISTICS
CAUSES OF CANCER
CURRENT CANCER TREATMENTS
- CHEMOTHERAPY

Table 1 ADVERSE EVENTS RELATED TO CHEMOTHERAPY
- STRATEGIES TO KILL CANCER USING BIOPHARMACEUTICALS
Table 2 STRATEGIES FOR TREATING CANCER WITH SELECTED BIOPHARMACEUTICALS
Table 2 (CONTINUED)
Table 3 SELECTED TUMOR ANTIGENS AND IMMUNOTHERAPIES
Table 3 (CONTINUED)
Table 4 SELECTED BIOPHARMACEUTICALS AS RADIOTHERAPEUTICS
Table 4 (CONTINUED)
- TYPES OF BIOPHARMACEUTICALS
  - MACROMOLECULES
    - Monoclonal Antibodies
    - Hormones and Cytokines
    - Other Protein Drugs
    - Peptides
    - Oligonucleotides
Table 5 SELECTED OLIGONUCLEOTIDE ANTISENSE DRUG CANDIDATES
Table 5 (CONTINUED)
- REGULATION
  - REGULATION IN THE U.S.
    - Drugs and Biologicals
Table 6 STAGES OF DRUG CANDIDATE REVIEW

APPLICATIONS FOR BIOPHARMACEUTICALS IN CANCER TREATMENT

TYPES OF CANCER

Table 7 INCIDENCE OF CANCER BY TYPE AND GENDER IN THE U.S., 2004
Table 8 BIOPHARMACEUTICAL DRUG CANDIDATES FOR BLADDER CANCER
Table 9 BIOPHARMACEUTICALS AS BRAIN CANCER THERAPIES
Table 10 BIOPHARMACEUTICALS APPROVED TO TREAT BREAST CANCER
Table 11 BIOPHARMACEUTICAL PIPELINE FOR BREAST CANCER
Table 11 (CONTINUED)
Table 12 GLOBAL REVENUES FROM BREAST CANCER BIOPHARMACEUTICALS, THROUGH 2008 ($ MILLION)
Figure 1 GLOBAL REVENUES FROM BREAST CANCER BIOPHARMACEUTICALS, 2004 AND 2008 ($ MILLION)
Table 13 BIOPHARMACEUTICAL PIPELINE TO TREAT CERVICAL CANCER
Table 14 BIOPHARMACEUTICALS APPROVED TO TREAT COLORECTAL CANCER
Table 15 BIOPHARMACEUTICAL THERAPIES FOR COLORECTAL CANCER IN CLINICAL TRIALS
Table 15 (CONTINUED)
Table 16 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT COLORECTAL CANCER, THROUGH 2008 ($ MILLION)
Figure 2 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT COLORECTAL CANCER, 2004 AND 2008 ($ MILLION)
Table 17 BIOPHARMACEUTICAL PIPELINE FOR TREATMENT OF GASTRIC CANCER
Table 18 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT GASTRIC CANCER, THROUGH 2008 ($ MILLION)
Table 19 BIOPHARMACEUTICAL PIPELINE TO TREAT HEAD AND NECK CANCER
Table 20 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT HEAD AND NECK CANCER, THROUGH 2008 ($ MILLION)
Table 21 BIOPHARMACEUTICALS APPROVED TO TREAT KIDNEY CANCER
Table 22 BIOPHARMACEUTICAL PIPELINE TO TREAT KIDNEY CANCER
Table 23 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT KIDNEY CANCER, THROUGH 2008 ($ MILLION)
Figure 3 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT KIDNEY CANCER, 2004 AND 2008 ($ MILLION)
Table 24 BIOPHARMACEUTICALS APPROVED TO TREAT LEUKEMIA OR LYMPHOMA
Table 25 BIOPHARMACEUTICAL PIPELINE TO TREAT LEUKEMIA AND LYMPHOMA
Table 26 GLOBAL REVENUES DERIVED FROM PHARMACEUTICALS TO TREAT LEUKEMIA AND LYMPHOMA, THROUGH 2008 ($ MILLION)
Figure 4 GLOBAL REVENUES DERIVED FROM PHARMACEUTICALS TO TREAT LEUKEMIA AND LYMPHOMA, 2001-2008 ($ MILLION)
Table 27 BIOPHARMACEUTICAL DRUG CANDIDATES TO TREAT LIVER CANCER
Table 28 BIOPHARMACEUTICALS IN CLINICAL TRIALS TO TREAT LUNG CANCER
Table 28 (CONTINUED)
Table 29 BIOPHARMACEUTICALS IN DEVELOPMENT TO TREAT MULTIPLE MYELOMA
Table 30 BIOPHARMACEUTICAL DRUG CANDIDATES TO TREAT NEUROBLASTOMA
Table 31 BIOPHARMACEUTICALS IN DEVELOPMENT TO TREAT OVARIAN AND UTERINE CANCER
Table 32 BIOPHARMACEUTICALS TO TREAT PANCREATIC CANCER
Table 33 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT PANCREATIC CANCER, THROUGH 2008 ($ MILLIONS)
Table 34 BIOPHARMACEUTICAL PIPELINE TO TREAT PROSTATE CANCER
Table 35 GLOBAL REVENUES FROM PHARMACEUTICALS TO TREAT PROSTATE CANCER, THROUGH 2008 ($ MILLION)
Figure 5 GLOBAL REVENUES FROM PHARMACEUTICALS TO TREAT PROSTATE CANCER, 2004-2008 ($ MILLION)
Table 36 APPROVED BIOPHARMACEUTICAL SARCOMA THERAPIES
Table 37 BIOPHARMACEUTICAL PIPELINE OF SARCOMA THERAPIES
Table 38 BIOPHARMACEUTICALS APPROVED TO TREAT SKIN CANCER
Table 39 BIOPHARMACEUTICAL PIPELINE TO TREAT SKIN CANCER
Table 39 (CONTINUED)
Table 40 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT SKIN CANCER, THROUGH 2008 ($ MILLIONS)
Figure 6 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT SKIN CANCER, 2001-2008 ($ MILLIONS)
Table 41 APPROVED BIOPHARMACEUTICALS TO TREAT CHEMOTHERAPY-RELATED CONDITIONS
Table 42 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT CHEMOTHERAPY RELATED CONDITIONS, THROUGH 2008
Figure 7 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT CHEMOTHERAPY RELATED CONDITIONS, 2001-2008
- SUMMARY TABLES - BIOPHARMACEUTICAL CANCER TREATMENTS
  - SUMMARY APPROVED BIOPHARMACEUTICALS FOR CANCER
Table 43 BIOPHARMACEUTICALS APPROVED TO TREAT ONCOLOGY INDICATIONS
Table 44 SUMMARY OF PROJECTED GLOBAL REVENUES FROM BIOTECH-ENABLED CANCER THERAPIES BY CANCER TYPE, THROUGH 2008 ($ MILLION)

BIOPHARMACEUTICAL DRUGS OR DRUG CANDIDATES

MACROMOLECULES
- MONOCLONAL ANTIBODIES
  - Product Pipieline

Table 45 FDA-APPROVED MONOCLONAL ANTIBODY THERAPIES FOR CANCER
Table 46 GLOBAL REVENUES FROM ANTIBODY THERAPIES FOR CANCER INDICATIONS, THROUGH 2008 ($ MILLION)
Figure 8 GLOBAL REVENUES FROM ANTIBODY THERAPIES FOR CANCER INDICATIONS, 2004 AND 2008 ($ MILLION)
Table 47 MONOCLONAL ANTIBODIES UNDER DEVELOPMENT AS ONCOLOGY DRUGS
Table 47 (CONTINUED)
Table 48 GLOBAL REVENUES DERIVED FROM HORMONE OR CYTOKINE ONCOLOGY DRUGS, THROUGH 2008 ($ MILLION)
Figure 9 GLOBAL REVENUES DERIVED FROM HORMONE OR CYTOKINE ONCOLOGY DRUGS, 2001-2008 ($ MILLION)
Table 49 HORMONE AND CYTOKINE DRUGS AND DRUG CANDIDATES
Table 50 PEPTIDE DRUG CANDIDATES FOR ONCOLOGY INDICATIONS
Table 51 OLIGONUCLEOTIDE DRUG CANDIDATES FOR CANCER INDICATIONS
Table 51 (CONTINUED)
- VACCINE THERAPIES
Table 52 SELECTED THERAPEUTIC VACCINE CANDIDATES FOR ONCOLOGY INDICATIONS
Table 52 (CONTINUED)
- VIRUS BASED BIOPHARMACEUTICALS
Table 53 VIRUS-BASED BIOPHARMACEUTICALS FOR ONCOLOGY INDICATIONS
Table 54 INDICATIONS FOR WHICH ADVEXIN IS BEING TESTED

STRUCTURE OF THE INDUSTRY

STRUCTURE OF THE INDUSTRY

Table 55 BIOTECHNOLOGY COMPANIES WITH APPROVED ONCOLOGY PRODUCTS
Table 56 ONCOLOGY BIOPHARMACEUTICAL MARKET LEADERS WORLDWIDE, 2003 SALES ($ BILLIONS)
- COMPANY PROFILES
  - ABGENIX
  - AGENNIX
  - ALTAREX CORP.
  - ALTOR BIOSCIENCE
  - AMGEN
  - ANTIGENICS
  - ANTISENSE PHARMA GMBH
  - APHTON
  - APTAMERA
  - ATTENUON, LLC
  - AVAX TECHNOLOGIES
  - ASTRAZENECA
  - AVENTIS SA
  - AVI BIOPHARMA
  - AVIDEX
  - BIOGEN IDEC
  - BIOMIRA
  - BIOVEX LTD.
  - BOSTON LIFE SCIENCES
  - CALLISTO PHARMACEUTICALS
  - CANCERVAX
  - CELL GENESYS
  - COLEY PHARMACEUTICAL GROUP
  - CORIXA
  - CURIS, INC.
  - CYTHERIS
  - CYTOGEN
  - CYTOGENIX
  - DIADEXU.S.
  - DYNAVAX
  - ENZON
  - EPEIUS BIOTECHNOLOGIES
  - FAVRILLE
  - GENENTECH
  - GENMAB A/S
  - GENTA
  - GENVEC
  - GENZYME
  - GERON
  - GLAXOSMITHKLINE
  - IDM, INC.
  - IMCLONE SYSTEMS, INC.
  - INGENEON
  - ILEX ONCOLOGY
  - IMMUNOGEN
  - IMMUNOMEDICS
  - INSMED
  - INTROGEN THERAPEUTICS
  - ISIS PHARMACEUTICALS, INC.
  - JOHNSON AND JOHNSON
  - MAXCYTE
  - MEDAREX
  - MEDIMMUNE
  - MERCK KGAA
  - METHYLGENE
  - MGI PHARMA
  - MOLECULAR ENGINES LABORATORIES
  - MORPHOTEK
  - NEOPHARM
  - ONCOGENEX TECHNOLOGIES
  - PANACEA PHARMACEUTICALS, INC.
  - PHARMEXA
  - PROGENICS PHARMACEUTICALS
  - PROTEIN DESIGN LABS
  - RAVEN BIOTECHNOLOGIES
  - REGENERON
  - ROCHE GROUP
  - SEATTLE GENETICS
  - STRESSGEN
  - THERION BIOLOGICS
  - TRANSMOLECULAR
  - U3 PHARMA
  - WYETH
  - XCYTE THERAPIES
  - XENOVA GROUP, PLC

LIST OF TABLES

Summary Table: PROJECTED GLOBAL REVENUES FROM BIOTECH-ENABLED CANCER THERAPIES BY APPLICATION TYPE, THROUGH 2008 ($ MILLION)
Table 1 ADVERSE EVENTS RELATED TO CHEMOTHERAPY
Table 2 STRATEGIES FOR TREATING CANCER WITH SELECTED BIOPHARMACEUTICALS
Table 3 SELECTED TUMOR ANTIGENS AND IMMUNOTHERAPIES
Table 4 SELECTED BIOPHARMACEUTICALS AS RADIOTHERAPEUTICS
Table 5 SELECTED OLIGONUCLEOTIDE ANTISENSE DRUG CANDIDATES
Table 6 STAGES OF DRUG CANDIDATE REVIEW
Table 7 INCIDENCE OF CANCER BY TYPE AND GENDER IN THE U.S., 2004
Table 8 BIOPHARMACEUTICAL DRUG CANDIDATES FOR BLADDER CANCER
Table 9 BIOPHARMACEUTICALS AS BRAIN CANCER THERAPIES
Table 10 BIOPHARMACEUTICALS APPROVED TO TREAT BREAST CANCER
Table 11 BIOPHARMACEUTICAL PIPELINE FOR BREAST CANCER
Table 12 GLOBAL REVENUES FROM BREAST CANCER BIOPHARMACEUTICALS, THROUGH 2008 ($ MILLION)
Table 13 BIOPHARMACEUTICAL PIPELINE TO TREAT CERVICAL CANCER
Table 14 BIOPHARMACEUTICALS APPROVED TO TREAT COLORECTAL CANCER
Table 15 BIOPHARMACEUTICAL THERAPIES FOR COLORECTAL CANCER IN CLINICAL TRIALS
Table 16 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT COLORECTAL CANCER, THROUGH 2008 ($ MILLION)
Table 17 BIOPHARMACEUTICAL PIPELINE FOR TREATMENT OF GASTRIC CANCER
Table 18 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT GASTRIC CANCER, THROUGH 2008 ($ MILLION)
Table 19 BIOPHARMACEUTICAL PIPELINE TO TREAT HEAD AND NECK CANCER
Table 20 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT HEAD AND NECK CANCER, THROUGH 2008 ($ MILLION)
Table 21 BIOPHARMACEUTICALS APPROVED TO TREAT KIDNEY CANCER
Table 22 BIOPHARMACEUTICAL PIPELINE TO TREAT KIDNEY CANCER
Table 23 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT KIDNEY CANCER, THROUGH 2008 ($ MILLION)
Table 24 BIOPHARMACEUTICALS APPROVED TO TREAT LEUKEMIA OR LYMPHOMA
Table 25 BIOPHARMACEUTICAL PIPELINE TO TREAT LEUKEMIA AND LYMPHOMA
Table 26 GLOBAL REVENUES DERIVED FROM PHARMACEUTICALS TO TREAT LEUKEMIA AND LYMPHOMA, THROUGH 2008 ($ MILLION)
Table 27 BIOPHARMACEUTICAL DRUG CANDIDATES TO TREAT LIVER CANCER
Table 28 BIOPHARMACEUTICALS IN CLINICAL TRIALS TO TREAT LUNG CANCER
Table 29 BIOPHARMACEUTICALS IN DEVELOPMENT TO TREAT MULTIPLE MYELOMA
Table 30 BIOPHARMACEUTICAL DRUG CANDIDATES TO TREAT NEUROBLASTOMA
Table 31 BIOPHARMACEUTICALS IN DEVELOPMENT TO TREAT OVARIAN AND UTERINE CANCER
Table 32 BIOPHARMACEUTICALS TO TREAT PANCREATIC CANCER
Table 33 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT PANCREATIC CANCER, THROUGH 2008 ($ MILLIONS)
Table 34 BIOPHARMACEUTICAL PIPELINE TO TREAT PROSTATE CANCER
Table 35 GLOBAL REVENUES FROM PHARMACEUTICALS TO TREAT PROSTATE CANCER, THROUGH 2008 ($ MILLION)
Table 36 APPROVED BIOPHARMACEUTICAL SARCOMA THERAPIES
Table 37 BIOPHARMACEUTICAL PIPELINE OF SARCOMA THERAPIES
Table 38 BIOPHARMACEUTICALS APPROVED TO TREAT SKIN CANCER
Table 39 BIOPHARMACEUTICAL PIPELINE TO TREAT SKIN CANCER
Table 40 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT SKIN CANCER, THROUGH 2008 ($ MILLIONS)
Table 41 APPROVED BIOPHARMACEUTICALS TO TREAT CHEMOTHERAPY-RELATED CONDITIONS
Table 42 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT CHEMOTHERAPY RELATED CONDITIONS, THROUGH 2008
Table 43 BIOPHARMACEUTICALS APPROVED TO TREAT ONCOLOGY INDICATIONS
Table 44 SUMMARY OF PROJECTED GLOBAL REVENUES FROM BIOTECH-ENABLED CANCER THERAPIES BY CANCER TYPE, THROUGH 2008 ($ MILLION)
Table 45 FDA-APPROVED MONOCLONAL ANTIBODY THERAPIES FOR CANCER
Table 46 GLOBAL REVENUES FROM ANTIBODY THERAPIES FOR CANCER INDICATIONS, THROUGH 2008 ($ MILLION)
Table 47 MONOCLONAL ANTIBODIES UNDER DEVELOPMENT AS ONCOLOGY DRUGS
Table 48 GLOBAL REVENUES DERIVED FROM HORMONE OR CYTOKINE ONCOLOGY DRUGS, THROUGH 2008 ($ MILLION)
Table 49 HORMONE AND CYTOKINE DRUGS AND DRUG CANDIDATES
Table 50 PEPTIDE DRUG CANDIDATES FOR ONCOLOGY INDICATIONS
Table 51 OLIGONUCLEOTIDE DRUG CANDIDATES FOR CANCER INDICATIONS
Table 52 SELECTED THERAPEUTIC VACCINE CANDIDATES FOR ONCOLOGY INDICATIONS
Table 53 VIRUS-BASED BIOPHARMACEUTICALS FOR ONCOLOGY INDICATIONS
Table 54 INDICATIONS FOR WHICH ADVEXIN IS BEING TESTED
Table 55 BIOTECHNOLOGY COMPANIES WITH APPROVED ONCOLOGY PRODUCTS
Table 56 ONCOLOGY BIOPHARMACEUTICAL MARKET LEADERS WORLDWIDE, 2003 SALES ($ BILLIONS)

LIST OF FIGURES

Summary Figure: PROJECTED GLOBAL REVENUES FROM BIOTECH-ENABLED CANCER THERAPIES BY APPLICATION TYPE, THROUGH 2008 ($ MILLION)
Figure 1 GLOBAL REVENUES FROM BREAST CANCER BIOPHARMACEUTICALS, 2004 AND 2008 ($ MILLION)
Figure 2 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT COLORECTAL CANCER, 2004 AND 2008 ($ MILLION)
Figure 3 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT KIDNEY CANCER, 2004 AND 2008 ($ MILLION)
Figure 4 GLOBAL REVENUES DERIVED FROM PHARMACEUTICALS TO TREAT LEUKEMIA AND LYMPHOMA, 2001-2008 ($ MILLION)
Figure 5 GLOBAL REVENUES FROM PHARMACEUTICALS TO TREAT PROSTATE CANCER, 2004-2008 ($ MILLION)
Figure 6 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT SKIN CANCER, 2001-2008 ($ MILLIONS)
Figure 7 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT CHEMOTHERAPY RELATED CONDITIONS, 2001-2008
Figure 8 GLOBAL REVENUES FROM ANTIBODY THERAPIES FOR CANCER INDICATIONS, 2004 AND 2008 ($ MILLION)
Figure 9 GLOBAL REVENUES DERIVED FROM HORMONE OR CYTOKINE ONCOLOGY DRUGS, 2001-2008 ($ MILLION)

Beyond Chemotherapy Battling Cancer with Biotechnology

TABLE OF CONTENTS

LIST OF TABLES

LIST OF FIGURES